1. Home
  2. IIPR vs CAPR Comparison

IIPR vs CAPR Comparison

Compare IIPR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Industrial Properties Inc.

IIPR

Innovative Industrial Properties Inc.

N/A

Current Price

$53.71

Market Cap

1.4B

Sector

Finance

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$33.33

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IIPR
CAPR
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
IIPR
CAPR
Price
$53.71
$33.33
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$45.00
$41.38
AVG Volume (30 Days)
306.6K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
14.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,270,465.00
Revenue This Year
$4.18
N/A
Revenue Next Year
N/A
$17,308.50
P/E Ratio
$10.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.58
$4.30
52 Week High
$70.19
$40.37

Technical Indicators

Market Signals
Indicator
IIPR
CAPR
Relative Strength Index (RSI) 58.40 69.97
Support Level $51.47 $22.09
Resistance Level $54.14 $40.37
Average True Range (ATR) 1.90 1.75
MACD 0.20 0.69
Stochastic Oscillator 72.37 71.61

Price Performance

Historical Comparison
IIPR
CAPR

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: